Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.53 |
| ▸ | TSHR | P16473 | 2/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.43 |
| ▸ | ELANE | P08246 | 8/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | PRKCA | P17252 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4316110 | 1.00 | ALDH1A1 (0.53) | ALDH1A1TSHRHSD17B10TDP1ELANE | |
| Methyl Alcohol SCHEMBL9630414 | 0.97 | ALDH1A1 (0.50) | ALDH1A1TSHRHSD17B10TDP1ELANE | |
| SCHEMBL21831923 | 0.97 | ALDH1A1 (0.50) | ALDH1A1TSHRHSD17B10TDP1ELANE | |
| SCHEMBL5780612 | 0.86 | ALDH1A1 (0.45) | ALDH1A1TSHRHSD17B10TDP1ELANE | |
| SCHEMBL65267 | 0.83 | ELANE (0.40) | ALDH1A1TSHRELANEPRKCA | |
| Ammonia Solution, Strong SCHEMBL25421893 | 0.80 | ELANE (0.39) | ALDH1A1TSHRELANEPRKCA | |
| SCHEMBL7026388 | 0.80 | ELANE (0.39) | ALDH1A1TSHRELANEPRKCA | |
| SCHEMBL3204404 | 0.80 | ALDH1A1 (0.39) | ALDH1A1TSHRHSD17B10TDP1ELANE | |
| SCHEMBL6921707 | 0.79 | ALDH1A1 (0.35) | ALDH1A1TSHRELANEPRKCA | |
| SCHEMBL22362392 | 0.78 | ELANE (0.37) | ALDH1A1TSHRELANEPRKCA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1393 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12612382-B2 | Process for preparing 6-substituted-1-(2H)-isoquinolinones and intermediate compound | VALO HEALTH INC. (US) | 2026-04-28 | — | — | US | claimed |
| CN-121574269-A | Starch modification hydrolysis method | 上海建工建材科技集团股份有限公司 | 2026-02-27 | — | — | CN | claimed |
| US-20250296923-A1 | PROCESS FOR PREPARING 6-SUBSTITUTED-1-(2H)-ISOQUINOLINONES AND INTERMEDIATE COMPOUND | VALO HEALTH, INC. (US) | 2025-09-25 | — | — | US | claimed |
| CN-119751333-A | Preparation method of N-alkyl-4-nitrophthalimide | 广东优巨先进新材料股份有限公司 | 2025-04-04 | — | — | CN | claimed |
| CN-119684399-A | Synthesis method of Val-Cit dipeptide linker | 浙江工业大学 | 2025-03-25 | — | — | CN | claimed |
| CN-119630643-A | Process and intermediate compounds for the preparation of 6-substituted-1- (2H) -isoquinolinones | 瓦洛健康公司 | 2025-03-14 | — | — | CN | claimed |
| US-20240287031-A1 | PROCESS FOR PREPARING 6-SUBSTITUTED-1-(2H)-ISOQUINOLINONES AND INTERMEDIATE COMPOUND | VALO HEALTH, INC. (US) | 2024-08-29 | — | — | US | claimed |
| US-20240287030-A1 | PROCESS FOR PREPARING 6-SUBSTITUTED-1-(2H)-ISOQUINOLINONES AND INTERMEDIATE COMPOUND | VALO HEALTH, INC. (US) | 2024-08-29 | — | — | US | claimed |
| EP-4402129-A1 | <SMALLCAPS/>? ? ?H? ? ? ? ?PROCESS FOR PREPARING 6-SUBSTITUTED-1-(2)-ISOQUINOLINONES AND INTERMEDIATE COMPOUND | Valo Health, Inc. (US) | 2024-07-24 | — | — | EP | claimed |
| WO-2024094637-A1 | PROCESS FOR THE PREPARATION OF CYCLIC KETONES | ARXADA AG (CH) | 2024-05-10 | — | — | WO | claimed |
| EP-0219196-B1 | SURFACE TREATMENT OF SOFT CONTACT LENSES | Sola U.S.A. Inc. (US) | 1990-05-09 | — | — | EP | claimed |
| EP-0239194-A2 | Methods for preparing hydroxy compounds and intermediates | SYMBICOM AB (SE) | 1987-09-30 | — | — | EP | claimed |
| US-4687816-A | USING ORGANIC ACID ANHYDRIDE | SOLA U.S.A. INC. (US) | 1987-08-18 | — | — | US | claimed |
| US-4666249-A | Surface-treated contact lens and method of producing | SOLA U.S.A. INC. (US) | 1987-05-19 | — | — | US | claimed |
| EP-0219196-A1 | Surface treatment of soft contact lenses | Sola U.S.A. Inc. (US) | 1987-04-22 | — | — | EP | claimed |
| EP-0157088-B1 | PROCESS FOR THE PREPARATION OF POLYISOCYANATES HAVING A BIURET STRUCTURE | BAYER AG (DE) | 1987-01-14 | — | — | EP | claimed |
| US-4625052-A | REACTING DIISOCYANATES WITH WATER IN PRESENCE OF TRI-SUBSTITUTED ACETIC ACIDS ANDOR ANHYDRIDES | BAYER AKTIENGESELLSCHAFT (DE) | 1986-11-25 | — | — | US | claimed |
| US-4603013-A | Estrane derivatives | SCHERING AKTIENGESELLSCHAFT (DE) | 1986-07-29 | — | — | US | claimed |
| EP-0051143-B1 | PROCESS FOR THE PREPARATION OF 3-BETA, 7-BETA-DIHYDROXY-DELTA-5 STEROIDS | SCHERING AKTIENGESELLSCHAFT (DE) | 1984-07-04 | — | — | EP | claimed |
| US-4416985-A | Process for preparing 3β,7β-dihydroxy-Δ5 -steroids | SCHERING, AKTIENGESELLSCHAFT (DE) | 1983-11-22 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240287031-A1 | PROCESS FOR PREPARING 6-SUBSTITUTED-1-(2H)-ISOQUINOLINONES AND INTERMEDIATE COMPOUND | ROCK1, ROCK2, CIT | ALDH1A1 1653/4885TSHR 4618/4885HSD17B10 1796/4885 |
| US-20250296923-A1 | PROCESS FOR PREPARING 6-SUBSTITUTED-1-(2H)-ISOQUINOLINONES AND INTERMEDIATE COMPOUND | ROCK1, ROCK2, CIT | ALDH1A1 1653/4885TSHR 4618/4885HSD17B10 1796/4885 |
| US-12612382-B2 | Process for preparing 6-substituted-1-(2H)-isoquinolinones and intermediate compound | ROCK1, RHOA, ABL1 | ALDH1A1 3101/4885TSHR 506/4885HSD17B10 3552/4885 |
| US-20240287030-A1 | PROCESS FOR PREPARING 6-SUBSTITUTED-1-(2H)-ISOQUINOLINONES AND INTERMEDIATE COMPOUND | ROCK1, ROCK2, CIT | ALDH1A1 1653/4885TSHR 4618/4885HSD17B10 1796/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.